Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (372)	9/1/2011 9:22:57 PM
From: John McCarthy	Respond to of 421

This might sound disingenuous - but I think its very good news for Iluvien. (a) Avastin (apparently) is being dumbed-down (dosed-down) by mom&pop "bacterial" shops. (b) Goodby Avastin (and $60 a shot) - maybe. (c) Avastin and Lucentis carry the same anchor - 1 shot every 4 to 6 wks vs 1 shot Iluvien every 36 -/+ months or so. (d) If (b) happens that leaves lasers/Lucentis/Iluvien -- or -- hole-in-the-eye vs $$ mucho dinero vs get a catarack fix with Iluvien. I am really more nervous as to why we may actually have to wait until November. There is some part of the efficacy (I guess) that I ain't fully understanding. regards John